Menlo Park, Calif., June 20, 2003
Nanosyn Inc. today announced that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its patent application claiming the solid phase component of the proprietary platform for efficient organic synthesis developed at Nanosyn (ANSTTM).
The new patent claims methods for the direct identification of compound structure following solid phase synthesis of a chemical library. An important feature of the methods is to reveal rapidly compounds that undergo unexpected chemical transformation thus allowing for highly efficient chemistry development on solid phase. The methods may be applied to any group of compounds originating from chemical reactions where one reactant is common to the synthetic transformation.
"This patent further demonstrates Nanosyn' ability to innovate and develop new approaches to accelerated and cost-efficient drug discovery" said Nikolai Sepetov, Chief Executive Officer of Nanosyn.
Nanosyn is a chemistry-based company specializing in the design, synthesis and analysis of small organic compounds for pharmaceutical and biotechnology industries. We put special emphases on custom synthesis, 'hit-to-lead' optimization, and development of screening libraries targeted for drug discovery. Nanosyn's unique proprietary technology ANSTTM yields PureQualityTM compounds enabling rapid identification of new drug candidates.
For more information please contact
Dr. Olga Issakova
3760 Haven Ave.
Menlo Park, CA 94025
Tel: (650) 853-7034
Fax: (650) 853-7033